Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16.

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

Author information

  • 1Micromet, Inc, 6707 Democracy Blvd, Bethesda, MD 20817, USA. dirk.nagorsen@micromet.com

Abstract

Severe side effects and few long-term remissions frequently limit the treatment of advanced malignant diseases. Bispecific antibodies are currently emerging as a new option for the treatment of malignant diseases, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis. Blinatumomab, a bispecific single-chain BiTE antibody construct with dual specificity for CD19 and CD3, is a front runner of this antibody class. We here summarize the current state of development of blinatumomab for the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL) and B-precursor acute lymphocytic leukemia (ALL). High response rates and durable remissions are observed in first clinical trials, indicating that T cells can be potently redirected for efficient and lasting elimination of malignant cells.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21419116
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk